Dow Jones

38,798.99

-0.22%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

IXHL

Incannex Healthcare (IXHL)

Incannex Healthcare Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IXHL

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
30/05/2024	07:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IXHL	Incannex Healthcare Ltd
30/05/2024	06:30	GlobeNewswire Inc.	Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	NASDAQ:IXHL	Incannex Healthcare Ltd
07/05/2024	06:30	GlobeNewswire Inc.	Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	NASDAQ:IXHL	Incannex Healthcare Ltd
16/04/2024	07:00	GlobeNewswire Inc.	Incannex Healthcare Inc. Quarterly Update, Q1 2024	NASDAQ:IXHL	Incannex Healthcare Ltd
28/02/2024	06:30	GlobeNewswire Inc.	Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	NASDAQ:IXHL	Incannex Healthcare Ltd
16/02/2024	06:30	GlobeNewswire Inc.	Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	NASDAQ:IXHL	Incannex Healthcare Ltd
14/02/2024	05:16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IXHL	Incannex Healthcare Ltd
01/02/2024	06:30	GlobeNewswire Inc.	Clarion Clinics Open for Psychedelic-Assisted Treatments	NASDAQ:IXHL	Incannex Healthcare Ltd
24/01/2024	15:05	GlobeNewswire Inc.	Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	NASDAQ:IXHL	Incannex Healthcare Ltd
18/01/2024	07:22	GlobeNewswire Inc.	Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	NASDAQ:IXHL	Incannex Healthcare Ltd
17/01/2024	06:30	GlobeNewswire Inc.	Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	NASDAQ:IXHL	Incannex Healthcare Ltd
21/12/2023	19:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IXHL	Incannex Healthcare Ltd
21/12/2023	15:05	GlobeNewswire Inc.	Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	NASDAQ:IXHL	Incannex Healthcare Ltd
20/12/2023	16:05	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:IXHL	Incannex Healthcare Ltd
06/12/2023	06:30	GlobeNewswire Inc.	Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	NASDAQ:IXHL	Incannex Healthcare Ltd
29/11/2023	12:40	GlobeNewswire Inc.	Incannex Healthcare Announces Completion of its Redomiciliation to the United States	NASDAQ:IXHL	Incannex Healthcare Ltd
16/11/2023	08:38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IXHL	Incannex Healthcare Ltd
16/11/2023	07:30	GlobeNewswire Inc.	Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC	NASDAQ:IXHL	Incannex Healthcare Ltd
08/09/2023	06:30	GlobeNewswire Inc.	Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023	NASDAQ:IXHL	Incannex Healthcare Ltd
24/08/2023	06:30	GlobeNewswire Inc.	Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD	NASDAQ:IXHL	Incannex Healthcare Ltd
22/08/2023	06:30	GlobeNewswire Inc.	Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed	NASDAQ:IXHL	Incannex Healthcare Ltd
08/08/2023	07:00	GlobeNewswire Inc.	Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening	NASDAQ:IXHL	Incannex Healthcare Ltd
28/07/2023	06:30	GlobeNewswire Inc.	Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement	NASDAQ:IXHL	Incannex Healthcare Ltd
26/07/2023	06:30	GlobeNewswire Inc.	Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis	NASDAQ:IXHL	Incannex Healthcare Ltd
21/07/2023	08:09	GlobeNewswire Inc.	Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea	NASDAQ:IXHL	Incannex Healthcare Ltd
18/07/2023	06:40	GlobeNewswire Inc.	Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea	NASDAQ:IXHL	Incannex Healthcare Ltd
13/07/2023	07:00	GlobeNewswire Inc.	Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis	NASDAQ:IXHL	Incannex Healthcare Ltd
10/07/2023	06:30	GlobeNewswire Inc.	Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq	NASDAQ:IXHL	Incannex Healthcare Ltd
06/07/2023	07:42	GlobeNewswire Inc.	Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)	NASDAQ:IXHL	Incannex Healthcare Ltd
30/06/2023	07:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IXHL	Incannex Healthcare Ltd